ELISA Analyzer Market Overview along with Company Profiles Product details Competitors and Forecast 2026

Enzyme Linked Immunosorbent Assay (ELISA) is a biochemical assay, which use antibodies and an enzyme-mediated color change to detect the presence of either antigen (proteins, peptides, and hormones) or antibody in sample. Enzyme-linked immunosorbent assay is used as diagnostic tool in medicine and analytical tool in biomedical research. ELISA analyzer is an instrument used for detecting the concentration and presence of analyte in the test sample. ELISA analyzer can be used are a part of workflow were reagents and consumables are fed to carry out ELISA and results are displayed on the screen attached to it, which is known as automated ELISA analyzer. Increasing array of products to ease the workflow is the major factor driving the ELISA analyzer market growth over the forecast period. Moreover, increasing prevalence of infectious disease and drug development are also expected to fuel the ELISA analyzer market growth over the forecast period. However, stringent regulatory policies for product approval are expected to hinder the new product launches, which in turn is restraining growth of the market.

ELISA Analyzer Market Dynamics

New product launches with increased sophistication and value added testing environment to enhance sensitivity coupled with compactness of product are expected to fuel growth of the ELISA analyzer market over the forecast period. For instance, in 2017, Siemens Healthineers, received CE approval for Atellica Solution, an automated immunoassay and chemistry analyzers in Europe, the U.S., South America, and Asia. The product has comprehensive menu of 170 assays, which include cardiac, thyroid, and reproductive tests. Furthermore, the company has pipeline of about 50 more assays, which are expected to be added to the present menu. In 2014, Sysmex Corporation launched HISCL-800, a compact and automated immunoassay system used for the immunochemistry testing. The product is claimed to be more compact as compared to other products of same series.

Download the PDF brochure:

https://www.coherentmarketinsights.com/insight/request-pdf/1850

ELISA technique holds promising results in diagnosis of health related problems. High prevalence of infectious disease and cancer are propelling growth of the ELISA analyzer market. For instance, according to World Health Organization (WHO), in 2016, an estimated cases of malaria in 91 countries across the globe were around 216 million, which increased by 5 million as compared to 2015. Moreover, funding and initiatives to eradicate the disease burden are expected to increase the adoption of diagnostic assay and advanced analyzer, in turn augment the ELISA analyzer market growth. Furthermore, increasing number of drug discovery programs by pharmaceutical and biopharmaceutical companies are propelling demands for improved and advanced instrument to ease with good quality results in less time as a part of the workflow. According to International Federation of Pharmaceutical Manufacturers & Associations, in 2015, new 56 medicines were launched, while currently more than 7,000 compounds are at different stages of development worldwide. Such drug discovery programmes prominently use ELISA in the clinical trial, in turn increasing adoption of ELISA analyzer.

ELISA Analyzer Market – Regional Analysis

Regional segmentation of the market by Coherent Market Insights includes North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America ELISA analyzer market holds dominant position in global market, owing to increasing burden of infectious disease, adoption of immunoassays in diagnosis, and presence of local market players. For instance, according to National Ambulatory Medical Care Survey, 2015, in the U.S. around 16.8 million visits were reported to physician offices for infectious and parasitic diseases. However, Asia Pacific ELISA analyzer market is expected to witness rapid growth, owing to increasing demand from emerging economies such as India, where large patient population demands for rapid and high-throughput technology for test and detection of disease.

ELISA Analyzer Market – Competitive Analysis

Key players operating in the ELISA analyzer market include Siemens Healthineers, Awareness Technology, Inc., Dynes Technologies, Inc., EUROIMMUN AG, Robimes, Gold Standard Diagnostics, Corp., BioTek Instruments, Inc., and Berthold Technologies GmbH & Co. KG.

Market players are adopting growth strategies such as merger, acquisition or geographical expansion. For instance, in 2016, Gold Standard Diagnostics, Corp. and R-BioPharma AG collaborated on multiple technology and marketing initiatives to leverages respective strength of both companies to expand product offering and geographic sales coverage. In 2013, Gold Standard Diagnostics, Corp. established distribution partnership for the ThunderBolt automated immunoassay analyzer in 18 countries since its launch in 2012.

Get HOLISTIC Request Sample Copy Of This Business Report:

https://www.coherentmarketinsights.com/insight/request-sample/1850

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Cancer Vaccines Market Benefit and Volume 2018 with Status and Prospect to 2026

Cancer is the second leading cause of morbidity and mortality worldwide. Major cause of cancer is gene mutation and rarely due to inherited genes. On the basis of the type of cell it initiates to form cancerous with, it is divided into carcinoma, lymphomas, leukaemias, brain tumors, and sarcomas. According to World Health Organization (WHO), 2017, nearly 1 in 6 deaths is due to cancer globally and around 70% of deaths from cancer occur in low- and middle-income countries. Moreover, it is projected that for next two decades, 70% of new cases are expected to be diagnosed globally. Advent of cancer vaccines can significantly reduce this numbers and lead a cancer-free life for the global population.

Key players in the global cancer vaccines market include, Astrazeneca Plc. (Medimmune, LLC.), Glaxosmithkline Plc., Merck & Co., Inc., Sanofi Pasteur, Aduro BioTech Inc., Sanpower Group, Astellas Pharma Inc., CSL Limited, Pfizer Inc., and Serum Institute of India Pvt. Ltd.

Download the PDF brochure:

https://www.coherentmarketinsights.com/insight/request-pdf/1209

Global Cancer Vaccines Market Taxonomy:

By Product Type: Preventive cancer vaccines, Therapeutic cancer vaccines

By Technology: Subunit Vaccines, Live Attenuated Vaccines, Conjugate Vaccines, Inactivated Vaccines, Recombinant Vector Vaccines, Viral Vector And DNA Cancer Vaccine,

By Application: Cervical cancer, Prostate cancer And Others

Development of new vaccines for treatment of different cancers is expected to fuel growth of the cancer vaccines market over the forecast period

Manufacturers in the cancer vaccines market are focusing on developing new vaccines in order to treat various cancers. Through this, they are expected to gain a competitive edge in the market and increase their market share. For instance, Gilead Science Inc., in 2017, acquired Kite Pharma Inc., which is involved in development of different type of immunotherapy and vaccines. Also, Treos Bio, in 2017, collaborated with Pharmaceutical Product Development, LLC (PPD), in order to conduct its first-in-human clinical trial for its cancer vaccine for metastatic colorectal cancer.

Increasing prevalence and incidence of different cancers is expected to favor growth of the cancer vaccines market

According to WHO, in 2015, about 8.8 million people died from cancer. Moreover, tobacco related cancers was responsible for 22% deaths, lung cancer accounted for 1.69 million deaths, liver cancer led to 788,000 deaths. Colorectal, stomach, and breast cancer are estimated to cause 774,000, 754,000, and 571,000 deaths, worldwide. Increasing prevalence is a major driving factor to fuel growth of the cancer vaccines market.

According to a research from University of Pittsburgh School of Medicine, in 2017, a high dose flu vaccine can be used to treat people aged between 54–64 years with chronic condition such as heart disease, lung disease, diabetes, and cancer. The study is recommended for clinical trials in geriatric population.

Also, in 2017, Swiss Biotech, developed VXM01 — an attenuated bacterial vaccine modified to express vascular endothelial growth factor receptor-2 (VEGFR2), stimulates cytotoxic (killer) T cells, which will destroy cells in the vasculature feeding tumor and allow greater infiltration of immune cells. This vaccine is expected to be used for treatment in colorectal cancer and glioblastoma. Click To Read More On Cancer Vaccines Market

Also, Coherent Market Insights has a proprietary database of pipeline biologics and biosimilars, called PHASE-XS. This database provides analytical data in addition to the clinical information of ongoing trials for biologics and biosimilars. An amalgamation of more than 30 parameters, PHASE-XS helps biotechnology and pharmaceutical companies to analyze the market trend, competition, and market potential. For more information or to access this database, kindly click on the below link or contact at [email protected]

https://www.coherentmarketinsights.com/phase-xs/

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Radiopharmaceuticals Market:Business Opportunities, Current Trends,Challenges in 2026

Radiopharmaceuticals are unique medicinal formulations that contain radioisotopes and are used in clinical applications for diagnosis and therapy. The facilities and procedures for production, use, and storage of radiopharmaceuticals are subject to license approval either by national or regional authorities such as Nuclear Regulatory Commission (NRC) of U.S, Atomic Energy Commission (AEC) of U.S., or Atomic Energy Regulatory Board (AERB) of India. Licensing includes compliance regarding pharmaceutical preparations and use of radioactive materials.

A radiopharmaceutical preparation is a medicinal product in a ready-to-use format containing a radionuclide suitable for human use. A kit for radiopharmaceutical preparation encloses a vial containing the non-radionuclide components of a radiopharmaceutical preparation in a sterilized and validated form, to which the appropriate radionuclide is added. Radiopharmaceuticals derived from the kits are intended to be used within 12 hours of preparation.

Technetium-99m – Widely used Radioisotope in Diagnostic Procedures fueling growth of the radiopharmaceuticals market

There are over 40 radioisotopes available for use in different therapies. Technetium-99m is the most widely used radioisotope in the diagnostic procedures. Technetium-99m is used as a radioactive tracer, and can be detected in the body by medical equipment (gamma cameras). It is well suited to the role, as it emits readily detectable gamma rays with photon energy of 140 keV. According to International Atomic Energy Agency, over 80% of the total nuclear diagnostic procedures performed worldwide use Technetium-99 as a radiotracer each year and hence, propels the radiopharmaceuticals market growth.

Get HOLISTIC Request Sample Copy Of This Business Report:

https://www.coherentmarketinsights.com/insight/request-sample/70

Radiopharmaceuticals use in Diagnostic and Therapeutic Application fuels growth of the nuclear medicine market

The chemical and physical identity is of vital importance, as during administration it targets certain tissues, binding sites, and biochemical pathways. The market is divided into two major areas, namely, diagnostic and therapeutic. Therapeutic applications of radiopharmaceuticals market include cardiology (myocardial perfusion), oncology (tumor imaging and localization), and neurology (cerebral perfusion). Radiopharmaceuticals such as iodine-131 or iodine-125 labeled m-iodobenzyl guanidine (MIGB) are used to treat pheochromocytoma and neuroblastoma. The therapeutic segment nuclear medicine market can be further sub-segmented on the basis of procedure into beta emitters, alpha emitters, and brachytherapy.

The diagnostic segment of radiopharmaceuticals market is classified into SPECT and PET. Single photon emission computed tomography (SPECT) adoption has grown steadily over the last decade and is used in the study of cerebral blood flow imaging. Positron emission tomography (PET) is a functional imaging technique used to observe metabolic processes in the body. System detects pairs of gamma rays emitted by a positron emitting radionuclide. SPECT radioisotopes are used for diagnosis of diseases such as cancer, cardiovascular diseases, and thyroid and neurological disorders.

Radiopharmaceuticals – Used in Hospitals for Diagnosis

End users of radiopharmaceuticals include hospitals, research institutes, and diagnostic labs. These can be used in hospitals for diagnosis and detection of various diseases such as bone-related pathology, bone pain, stress fracture, bone infections, and spread of cancer in the bone. They are also used in detection and scanning such as in neurology and cardiology.

Application of Radiopharmaceuticals across the Globe

Radiopharmaceuticals are widely used in North America, mainly due to availability of advanced healthcare infrastructure, technological advancements, superior medical facilities, and supportive government support. These are also widely used in Europe due to new procedures for diagnosis of diseases and robust medical infrastructure in the region. Radiopharmaceuticals market is projected to witness rampant growth in Asia due to rapid rise in research work in the sector and rising public awareness.

Key players involved in Nuclear Medicine market

The market is fragmented, with the presence of various major players such as Kimberly-Clark Corporation, Eli Lilly and Company, Lantheus Medical Imaging Inc., Ampio Pharmaceuticals Inc., GE Healthcare, Piramal Imaging, Covidien Plc., Cardinal Health, Iso Tex Diagnostics, Inc., Jubilant DraxImage Inc., Bayer HealthCare Pharmaceuticals Inc., Bracco Diagnostic Inc., Navidea Biopharmaceuticals, Nordion Inc., Spectrum Pharmaceuticals, Inc., Mallinckrodt Plc., Bio-Nucleonics Inc., and IBA-Molecular.

Click To Reading More On Radiopharmaceuticals Market

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:[email protected]

Global Prefilled Syringes Market Present Chances, Trends, Value Chain And Stakeholder Analysis 2018-2026

Prefilled syringes are ready to use pharmaceutical products used to deliver parenteral medications. These are mainly used for treatment of chronic conditions that require long-term and self-administration of medication. Prefilled syringes are the ideal choice for single-dose drugs, offering easy-to-use fixed dosage options, thereby helping pharmaceutical companies control costs by minimizing drug overfill, minimize microbial contamination and reduce dosing errors. Prefilled syringes make injections easier and safer for both doctors and patients, with the patient always receives the right amount of dosage without complications.

Download the PDF brochure: https://www.coherentmarketinsights.com/insight/request-pdf/162

The prefilled syringes market is expected to gain steady traction in the foreseeable future, with the success and growth of biologics, increased global vaccination, increased drug self-administration trend, technological advancements in the manufacture of PFS, and development of advanced PFS would further augment market growth. For instance, Safelia auto injector developed by Nemera in 2017 won the ‘Patient Centricity & Customization’ innovation award at Pharmapack. Safelia is an innovative auto injector for prefilled syringes, available in variable sizes, suitable for large volume and high viscosity delivery through thinner needles.

Market Dynamics

Minimum environment exposure, easy administration, better patient compliance and 100% bioavailability are the factors expected to drive the prefilled syringes market growth in the forecast period. According to the World Journal of Pharmacy and Pharmaceutical Sciences 2016, more than 3.5 billion prefilled syringes are produced and used annually by patients and healthcare providers for the treatment of broad spectrum of conditions. The technological innovations and developments of prefilled syringes are contributing to the market growth. For instance, Gerresheimer introduced metal-free Luer Lock Gx RTF Syringe in 2017, without tungsten to create perfect primary packaging material for the biotechnologically manufactured active ingredients that ideally exclude the possibility of contamination with metal. However, availability of alternative systems such as nanopatches, microneedles, connected delivery devices, limited shelf life and stability issues of the drugs are the factors restraining the market growth.

Market Taxonomy

This report segments the global prefilled syringes market on the basis of drug type, material and geography. On the basis of product type, the prefilled syringes market is categorized into biologics, vaccines, insulin and others. Biologics are further categorized into monoclonal antibodies, blood products and others. Vaccines are further categorized into conjugated vaccines, live attenuated vaccines, recombinant vaccines and others. On the basis of material, the prefilled syringes market is categorized into glass and plastic/polymer. For comprehensive understanding of market dynamics, the global prefilled syringes market is analyzed across key geographical regions namely North America, Latin America, Europe, Asia Pacific, Middle East and Africa. Each of these regions is analyzed on basis of market findings across major countries in these regions for a macro-level understanding of the market.

Key features of the study:

This report provides in-depth analysis of the prefilled syringes market and its application, market size (US$ Million) and Cumulative Annual Growth Rate (CAGR (%)) for the forecast period: 2017 – 2025, considering 2017 as the base year.

It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market.

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by the leading players.

It profiles leading players in the global prefilled syringes market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies and future plans.

Key companies covered as a part of this study include Becton Dickinson & Co., Gerresheimer, Medtronic, Baxter International, SCHOTT AG, West Pharmaceuticals, Vetter International, Unilife Corporation, Stevanato Group and Terumo Corporation.

Click To Read More On Global Prefilled Syringes Market